+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.

Age: 18Years +All GendersPhase 3
220 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
E

Actively Recruiting

Researchers are studying the effects and safety of berobenatide PF-08653944 in adults with overweight or obesity, including some with type 2 diabetes. This Phase 3 study compares berobenatide to a placebo to understand its impact on weight loss and safety. The trial involves about 950 adults to provide comprehensive data on the treatments effects. Participants will receive either berobenatide or a matching placebo by a shot under the skin in the belly area. The study uses a randomized, double-blind design with parallel groups. Doses are administered monthly, and the study treatment is given by subcutaneous injection. The trial will last about 20 months, with participants attending approximately 15 site visits and 2 phone visits. During the study, participants will have regular assessments including body weight and waist measurements, blood pressure, blood tests for glucose, insulin, cholesterol, and inflammatory markers, as well as questionnaires about quality of life and eating behavior. Safety monitoring will track adverse events and serious side effects. The main outcome assessed is the percent change in body weight from baseline to week 72, providing insight into the treatments impact over time.

Age: 18Years +All GendersPhase 3
72 locations
C

Actively Recruiting

Researchers are evaluating a surgical approach called Complete Mesocolic Excision with Central Vascular Ligation CMECVL compared to standard right hemicolectomy in patients with malignant tumors located in the right or proximal transverse colon. This Italian randomized controlled trial focuses on patients with stage II-IV colon cancer and aims to determine differences in disease-free survival as the primary outcome. The study also looks at safety, oncologic results, surgical quality, and quality of life as secondary outcomes. Participants will be randomly assigned to one of two groups one undergoing the conventional non-CME right hemicolectomy and the other receiving the CMECVL procedure. The CMECVL technique involves removing lymphovascular tissue at the origin of supplying vessels and preserving the mesocolon as an intact envelope. Various surgical approaches, including open, laparoscopic, or robotic surgery, are allowed. Surgeons decide the type of anastomosis and drain placement. The trial plans to enroll 416 patients over one and a half years, with five years of postoperative follow-up. During the study, patients will be monitored at 1, 4, 12, 24, 36, and 60 months after surgery. Researchers will collect demographic, baseline, perioperative, and postoperative data, evaluating outcomes such as disease-free survival at three years, safety measures including operative time and complications, overall survival, and quality of life. The total study duration is expected to be six and a half years, providing both short- and long-term information on these surgical methods.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
14 locations
E

Actively Recruiting

This research aims to investigate the effectiveness of play-based rehabilitation as usual care for children with cerebral palsy, a condition that affects movement and posture development and often involves other challenges like epilepsy and cognitive impairments. The study will also compare two rehabilitation formats intensive care provided in hospital inpatient units and extensive care delivered in community rehabilitation centers, to see if the timing of treatment affects outcomes. Children will receive either an extensive rehabilitation program consisting of 3-hour weekly sessions for 15 weeks in outpatient settings or an intensive program with 3-hour daily sessions, 5 days a week for 3 weeks in hospital care units. Both treatments include the same total dose of therapy and focus on goals involving gross motor skills, manipulative abilities, visual, and visual-cognitive functions. Participants will be assessed at the start, immediately after treatment, and at an 8-month follow-up using measures such as the Functional Independence Measure for children WeeFIM, the Gross Motor Function Measure 88 GMFM-88, and the Behavior Rating Inventory of Executive Function for preschool children. The study involves regular monitoring to evaluate the rehabilitation impact over time and to adjust care plans as needed, with total participation lasting through the follow-up period.

Age: 36Months - 5YearsAll Genders
6 locations
O

Actively Recruiting

This research aims to assess how well the Dehydration Readmission After Ileostomy Prediction DRIP score is used and how often its recommended care steps are applied to prevent dehydration and hospital readmissions in patients who have an ileostomy after elective colorectal surgery. The study focuses on patients at risk of dehydration, a common complication after ileostomy due to fluid loss through the stoma, which can lead to serious health issues and readmission. The study is prospective and observational, involving multiple Italian colorectal surgical centers. Patients undergoing ileostomy creation after elective colorectal resection will be observed for adherence to the DRIP scoring system and its preventive care protocol. The DRIP score categorizes patients into five risk levels from very low to very high, guiding different interventions such as pre-discharge education, intravenous fluids at home, antidiarrheal medications, nursing follow-up, phone check-ins, and outpatient visits with blood tests. Data collection will occur from May 2025 to April 2026, with a six-month follow-up period. Participants will have their clinical data recorded, including stoma care details, hydration status, creatinine levels, and post-discharge care measures. Researchers will track the application of DRIP scores, adherence to care strategies, and readmission rates at 30, 90, and 180 days. Data will be entered securely and analyzed to identify factors influencing readmission and dehydration. The study aims to improve patient outcomes by optimizing dehydration prevention and reducing hospital readmissions after ileostomy surgery.

Age: 18Years +All Genders
7 locations
T

Actively Recruiting

Millions of children worldwide are diagnosed each year with neurodevelopmental disabilities, which include a variety of conditions such as genetic syndromes and brain injuries like cerebral palsy. These children often face challenges in communication, especially in social and interactive skills necessary for language development. This trial aims to assess whether an intervention involving parents and focusing on early social and communication skills can improve outcomes better than standard speech therapy in children aged 6 months to 5 years with neurodevelopmental disabilities. The study compares two groups one receives a parent-involved intervention called SPEAK, focusing on early socio-communicative and intersubjective skills, while the other undergoes standard speech therapy. Both interventions consist of eight weekly sessions lasting 45 minutes each over two months. The SPEAK intervention includes guided parent participation during activities like playtime and snack time, helping parents observe and support their childs social communication. Standard speech therapy targets vocalization, language understanding, and speech production without active parent involvement. Participants and their parents will undergo assessments before and after the interventions to evaluate the childs language, social, and communication development, as well as parenting behaviors through video-recorded parent-child interactions. Additional evaluations will measure early cognitive and emotional development. The study monitors session attendance and withdrawal reasons to track adherence. The goal is to understand how these interventions impact childrens development and parent-child interactions over the two-month treatment period.

Age: 6Months - 59MonthsAll GendersPhase Not Applicable
9 locations
P

Actively Recruiting

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.

Age: 65Years +All GendersPhase 3
789 locations
E

Actively Recruiting

Researchers are evaluating the investigational drug omecamtiv mecarbil to see if it can reduce the risk of serious effects related to heart failure, such as hospitalization, heart transplantation, or death, in patients with symptomatic heart failure with severely reduced ejection fraction HFrEF. This Phase 3 trial compares the safety and effectiveness of omecamtiv mecarbil against a placebo in patients with this condition. Participants will be randomly assigned to receive either omecamtiv mecarbil or a placebo. Those in the omecamtiv mecarbil group will take oral tablets twice daily with doses adjusted based on drug levels in their blood 25, 37.5, or 50 mg. The treatment continues until at least 850 participants experience a heart failure event or cardiovascular death. This is a double-blind study, meaning neither participants nor study staff know who receives the drug or placebo. During the study, participants will be monitored up to about 3 years. Researchers will track occurrences of cardiovascular death, heart failure events, device implantations, heart transplants, and strokes. Participants will have regular visits and assessments to monitor their health and study outcomes. Safety and efficacy data will be collected until the study concludes when the required number of events has occurred.

Age: 18Years - 85YearsAll GendersPhase 3
213 locations